Market Trend Analysis: The Impact of Recent Advances on the Therapeutic Plasma Exchange Market

The therapeutic plasma exchange market is on track for substantial growth over the coming years, driven by innovations in treatment technologies and increasing demand for advanced therapies. This market is evolving rapidly as healthcare providers seek more effective and efficient solutions for managing autoimmune and other complex disorders. Here, we explore the anticipated market size, key players, growth drivers, and major trends shaping the industry.

Forecasted Expansion of the Therapeutic Plasma Exchange Market
The therapeutic plasma exchange market is projected to reach a value of $2.4 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.0%. This anticipated growth is fueled by rising demand for cutting-edge autoimmune therapies, broader adoption of membrane separation technology, and the growth of outpatient apheresis services. Additional factors include increased investments in blood purification technologies and a stronger emphasis on personalized immunological treatments. Key market trends during this period are expected to involve a surge in automated plasma exchange systems, extended use of therapeutic plasma exchange (TPE) in neurological disorders, growing need for high-efficiency separation technologies, expansion of apheresis units in hospitals, and enhanced focus on safety and monitoring protocols.

Download a free report of the therapeutic plasma exchange market report:
https://www.thebusinessresearchcompany.com/report/therapeutic-plasma-exchange-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Prominent Companies Leading the Therapeutic Plasma Exchange Market
Several influential companies play a major role in the therapeutic plasma exchange sector. These include Medica S.p.A., Fresenius SE and Co. KGaA, Medtronic Plc., Asahi Kasei Corporation, Toray Industries Inc., Baxter International Inc., B Braun Melsungen AG, Terumo Corporation, Kaneka Corporation, Octapharma AG, Haemonetics Corporation, Miltenyi Biotec Technology and Trading Co. Ltd., Macopharma SA, Cerus Corporation, Apellis Pharmaceuticals Inc., ImmunoTek Bio Centers LLC, CytoSorbents Corporation, and Kawasumi Laboratories America Inc.

A notable strategic move occurred in October 2025 when Accord Plasma B.V., a Netherlands-based provider specializing in plasma-derived medicines and large-scale fractionation services, acquired Prothya Biosolutions Belgium BV. This acquisition enhances Accord Plasma's global plasma therapy capabilities by integrating Prothya's European expertise, expanding production capacity, and improving access to critical plasma-derived therapies across multiple regions. Prothya Biosolutions operates significant plasma fractionation facilities and collection centers in Belgium, supplying essential plasma-based treatments.

View the full therapeutic plasma exchange market report:
https://www.thebusinessresearchcompany.com/report/therapeutic-plasma-exchange-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Market Trends Supporting Therapeutic Plasma Exchange Growth
Industry leaders are focused on advancing automation, improving device safety, and enhancing system efficiency to encourage wider clinical adoption and simplify workflows. Automation involves incorporating technologies that perform tasks with minimal human intervention. For example, in November 2024, Terumo BCT, a US-based medical device manufacturer, released a software update (V12.1) for its Spectra Optia Apheresis System. This update improved usability, strengthened cybersecurity, and optimized workflow features such as automatic pump pause during single needle exchange and alarm reduction. The system supports therapeutic plasma exchange with a plasma removal efficiency averaging 87%, a low extracorporeal volume of 141 mL, and a median platelet loss of only 1.0%. These advancements in automation and safety are driving increased adoption of TPE in hospitals and specialty clinics, though challenges remain due to high capital costs and the need for trained personnel in resource-limited settings.

Therapeutic Plasma Exchange Market Segmentation Overview
The market for therapeutic plasma exchange is categorized into several segments:
1) By Type: Therapeutic Plasma Exchange (TPE), Double Filtered Plasmapheresis (DFPP)
2) By Indication: Neurological Disorders, Hematological Disorders, Renal Disorders, Metabolic Disorders, Other Indications
3) By Technology: Centrifugation, Membrane Separation
4) By End User: Blood Collection Centers, Hospitals and Clinics, Transfusion Centers, Other End Users

Further subsegments include:
- Therapeutic Plasma Exchange (TPE): Manual TPE, Automated TPE
- Double Filtered Plasmapheresis (DFPP): Single-Stage DFPP, Multi-Stage DFPP

These diverse segments highlight the market's comprehensive scope and the variety of therapeutic approaches employed in patient care.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.